Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Hanwha Aerospace signed a supply contract worth approximately KRW 343.0B with the Defense Acquisition Program Administration (DAPA) for the 3rd mass production of 230mm-class multiple rocket launchers (launchers and ammunition transport vehicles).
📊 [Key Disclosure Details & Summary of Figures]
- Company Name: Hanwha Aerospace Co., Ltd.
- Ticker Symbol: 012450
- Disclosure Type: Single Sales/Supply Contract
- Disclosure Date: 2024-11-15
- Contract Title: 3rd Mass Production of 230mm-Class Multiple Rocket Launchers (Launchers and Ammunition Transport Vehicles)
- Contract Counterparty: Defense Acquisition Program Administration (DAPA)
- Contract Amount: KRW 342.97B (KRW 342,971,650,000)
- Ratio to Recent Revenue: 3.66% (Based on 2023 consolidated revenue of KRW 9,359,005,981,309)
- Sales/Supply Region: Republic of Korea
- Contract Period: 2024-11-15 ~ 2026-12-20
- Contract Date: 2024-11-15
- Other Remarks: Contract period and amounts are subject to change during execution
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Contract Execution and Revenue Recognition
This disclosure details a supply contract for the 3rd mass production of 230mm-class multiple rocket launchers with the South Korean Defense Acquisition Program Administration. Tracking how delivery progress is reflected in revenue and operating income on consolidated financial statements over the contract period (November 15, 2024, to December 20, 2026) is essential for understanding the direct financial contribution of this order. Quarterly progress and changes in order backlog can be verified in the “Business Overview – Revenue and Order Status” section of upcoming Periodic Reports (Quarterly, Half-Yearly, or Annual Business Reports).
📢 Disclaimer and Source Notice
Source: This content was newly structured and generated based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
